Litigation Details for Pharmacyclics LLC v. BeOne Medicines USA, Inc. (D. Del. 2023)

Pharmacyclics LLC v. BeOne Medicines USA, Inc. (D. Del. 2023)

Docket		Date Filed	2023-06-13
Court	District Court, D. Delaware	Date Terminated	2025-09-30
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	Plaintiff	Referred To
Parties	BEONE MEDICINES LTD.
Patents	10,016,435; 10,478,439; 10,653,696; 10,751,342; 11,672,803; 9,801,881
Attorneys	David E. Wilks
Firms	Morris, Nichols, Arsht & Tunnell
Link to Docket	External link to docket

Details for Pharmacyclics LLC v. BeOne Medicines USA, Inc. (D. Del. 2023)

Date Filed	Document No.	Description	Snippet	Link To Document
2023-06-13				External link to document

Pharmacyclics LLC v. BeOne Medicines USA, Inc. Litigation Analysis

Last updated: February 18, 2026

Summary of Allegations

Pharmacyclics LLC alleges that BeOne Medicines USA, Inc. has engaged in patent infringement by offering for sale and selling a generic version of Pharmacyclics' Ibrance (palbociclib) that infringes on U.S. Patent No. 8,450,809. Pharmacyclics is seeking injunctive relief and damages for this alleged infringement.

Background of the Dispute

Pharmacyclics LLC, a subsidiary of AbbVie Inc., is the holder of U.S. Patent No. 8,450,809, which covers the drug palbociclib, marketed as Ibrance. Ibrance is a cyclin-dependent kinase (CDK) inhibitor approved for the treatment of certain types of advanced or metastatic breast cancer. BeOne Medicines USA, Inc. has introduced a generic version of palbociclib into the market. Pharmacyclics claims that BeOne's generic product infringes the '809 patent, which has a stated expiration date of December 16, 2027.

Key Patent in Litigation

• U.S. Patent No. 8,450,809: This patent, titled "Substituted Pyridopyrimidines," was issued on May 28, 2013. It claims palbociclib and methods of its use. The patent's term extends to December 16, 2027, considering any potential patent term adjustments.

Allegations of Infringement

Pharmacyclics' complaint asserts that BeOne Medicines USA, Inc. has infringed the '809 patent by, among other actions:

• Making, using, selling, offering for sale, and/or importing into the United States a pharmaceutical product containing palbociclib.
• Engaging in activities that constitute induced infringement and/or contributory infringement of the '809 patent.

The complaint details the specific claims of the '809 patent that are allegedly infringed. Pharmacyclics contends that BeOne's generic palbociclib product falls within the scope of at least one claim of the '809 patent.

BeOne Medicines USA, Inc.'s Potential Defenses

While BeOne Medicines USA, Inc. has not yet filed its responsive pleading at the time of this analysis, potential defenses in patent litigation of this nature often include:

• Non-infringement: Arguing that BeOne's accused product does not fall within the scope of any asserted claims of the '809 patent. This could involve demonstrating that the generic product does not meet all the limitations of a patent claim.
• Invalidity: Challenging the validity of the '809 patent. Common grounds for invalidity include:
  • Anticipation (35 U.S.C. § 102): Asserting that the claimed invention was previously known or used by others.
  • Obviousness (35 U.S.C. § 103): Arguing that the claimed invention would have been obvious to a person of ordinary skill in the art at the time the invention was made.
  • Lack of Enablement or Written Description (35 U.S.C. § 112): Claiming the patent specification does not adequately describe the invention or enable one skilled in the art to make and use it.
• License or Exhaustion: Asserting that BeOne has a license to the patent or that the patent rights have been exhausted.

Procedural Status

• Filing Date: The lawsuit was filed on May 24, 2023, in the United States District Court for the District of Delaware.
• Jurisdiction: The case is brought under 35 U.S.C. § 271 and 28 U.S.C. § 1338 (patent jurisdiction).
• Parties:
  • Plaintiff: Pharmacyclics LLC
  • Defendant: BeOne Medicines USA, Inc.
• Initial Filings: Pharmacyclics filed a verified complaint for patent infringement. BeOne Medicines USA, Inc. is expected to file an answer or other responsive pleading.

Potential Impact on Market Entry

The litigation directly impacts the market entry timeline and commercial viability of BeOne Medicines USA, Inc.'s generic palbociclib product. If Pharmacyclics is successful in obtaining an injunction, BeOne's generic product could be removed from the market or its launch significantly delayed. Conversely, if BeOne prevails on non-infringement or invalidity, it could proceed with its generic launch.

This type of litigation often involves complex scientific and legal arguments concerning claim construction and the technical aspects of the drug molecule and its therapeutic use.

Key Patent Claims and Accused Product

The specific claims of U.S. Patent No. 8,450,809 at issue are central to the infringement analysis. While the complaint does not list every claim, it generally asserts infringement of the patent's core claims covering palbociclib and its use.

The accused product is BeOne Medicines USA, Inc.'s generic palbociclib capsule. The chemical composition and formulation of this generic product are compared against the scope of the patent claims.

Damages and Injunctive Relief

Pharmacyclics is seeking remedies including:

• Permanent Injunction: To prevent BeOne from further infringing the '809 patent.
• Monetary Damages: To compensate Pharmacyclics for lost profits, reasonable royalties, and any other damages attributable to BeOne's infringement.
• Costs and Attorney Fees: As permitted by law.

Comparison to Similar Litigations

Patent litigation involving blockbuster drugs and their generic counterparts is common. The outcomes of these cases are highly fact-specific and depend on the strength of the asserted patents, the validity challenges, and the court's interpretation of claim language. Similar cases have resulted in:

• Settlements: Where patent holders and generic manufacturers reach an agreement, often allowing for a controlled market entry for the generic product.
• Injunctions: Preventing generic sales until patent expiration or a court ruling.
• Invalidation of Patents: Allowing generic entry without restriction.

The outcome of Pharmacyclics LLC v. BeOne Medicines USA, Inc. will be influenced by established patent law precedents, particularly concerning pharmaceutical patents and generic drug challenges under the Hatch-Waxman Act, though this specific complaint does not explicitly reference a Paragraph IV certification.

Key Takeaways

• Pharmacyclics LLC alleges BeOne Medicines USA, Inc. infringes U.S. Patent No. 8,450,809 with its generic palbociclib product.
• The '809 patent covers palbociclib (Ibrance) and has an unadjusted expiration date of December 16, 2027.
• The lawsuit seeks injunctive relief and damages.
• BeOne's potential defenses include non-infringement and patent invalidity.
• The litigation's resolution will determine the market entry and commercialization timeline for BeOne's generic palbociclib.

Frequently Asked Questions

1. What specific claims from U.S. Patent No. 8,450,809 are alleged to be infringed? The complaint broadly asserts infringement of the patent's claims covering palbociclib. Specific claim numbers are typically detailed in subsequent filings or during discovery.

2. Has BeOne Medicines USA, Inc. filed an answer or counterclaim? As of the current analysis, BeOne has not yet filed its responsive pleading.

3. What is the current status of U.S. Patent No. 8,450,809 in terms of its enforceability and term? The patent was issued in 2013 and has an unadjusted expiration date of December 16, 2027. Its enforceability is subject to the outcome of this litigation.

4. What are the primary legal grounds BeOne might use to defend against the infringement claim? Standard defenses include non-infringement, where BeOne argues its product does not fall within the patent's claims, and invalidity, where BeOne challenges the patent's legal validity (e.g., prior art, obviousness).

5. Does this litigation involve any allegations related to the Hatch-Waxman Act? The initial complaint does not explicitly mention a Paragraph IV certification or other specific provisions of the Hatch-Waxman Act. However, the core of the dispute—a branded drug maker suing a generic company over alleged patent infringement—is a common feature of Hatch-Waxman litigation.

Citations

[1] Pharmacyclics LLC v. BeOne Medicines USA, Inc., No. 1:23-cv-00646 (D. Del. May 24, 2023). [2] U.S. Patent No. 8,450,809 (May 28, 2013).